



SINCLAIR PHARMA PLC

Analyst R&D meeting

London, UK, 29 June 2005: Sinclair Pharma plc ("Sinclair" or the "Company") (SPH.L), the specialty pharmaceutical company, announces that it is today holding an R&D briefing in London for investors and analysts. The briefing will focus on the Company's team, processes, products and R&D strategy. The Company also announces today current trading and, in separate announcement, additional product newsflow. The key speakers at the R&D presentation include:

- Dr. Michael Flynn, Sinclair Chief Executive will give an introduction and overview and introduce Sinclair Executives.
- Dr William Abramovits, principal investigator of a recent Atopiclair™ multi-center study performed on the Sinclair product in the US will make a presentation on the positive results.
- Prof Rolf Attstrom, a distinguished periodontal disease specialist, based at the renowned University of Lund in Sweden will make a presentation about periodontal disease and the use of Decapinol®.
- Company Executives will present on current developments and pipeline.
- Jerry Randall, ACA, Chief Financial Officer, will summarise the meeting.

The agenda for the R&D session is summarized below:

New Skin Products

SPHD 400 – A new topical product concept for the treatment of psoriasis.

Atopiclair™ Fluid – A fluid formulation of Atopiclair™. Application over large areas of the body is made easier for patients with atopic dermatitis or contact dermatitis.

Dermachronic – A non allergenic general use moisturiser and cleanser for patients with sensitive skin.

New products for oral care

Aloclair® patch – A soluble patch for application to single large ulcers to treat pain and protect the ulcer from trauma and irritation.

Alogon™ Spray – An easy to use treatment for sore throat.

Decapinol® toothpaste – A toothpaste (incorporating Decapinol) used for the treatment of gingivitis.

Decapinol® Gel – A 'professional use only' product for the intensive treatment of gum infections.

SPH0200 – A product combining Decapinol with polymer technology to create a longer acting once daily treatment for gingivitis.



MORE

New Products for Eye diseases

SPHP 700 – A new product concept for the treatment of dry eye syndrome.

SPH 720 - A non steroid product for the treatment of inflammatory conditions of the eye such as seasonal allergic conjunctivitis.

Sinclair will also touch on early stage projects including SPHD 420 for the treatment of acne and SPHR 900 for herpes simplex.

Trading update

Sinclair expects to finish the year to June 2005 with total revenues ahead of market expectations and significantly above the reported revenue for the previous year. This is mainly due to the inclusion of the Atopiclair™ license fees from US licensee Chester Valley Pharmaceuticals. As a consequence of the stronger sales, operating losses are expected to be better than anticipated although the full benefit of this is reduced by a change of business mix.

Commenting Chief Executive, Dr Michael Flynn said:

"We aim to develop products which are needed to satisfy unmet patient needs and which offer clear differentiating features and benefits over the competition. Most of our products come from patented technology platforms and from combinations of more than one patented technology. Up to now we have informed the market about products when we are actually in the registration process but having had good regulatory success to date with products which have passed proof of concept we are now unveiling a major part of our pipeline. We believe that we will be able to establish strong claims and have protected products which have the potential to compete with market leaders. We now have a portfolio of products which we believe can competitively address a large part of the US\$8 billion skin diseases market and most painful conditions of the mouth and throat. We are now extending the use of our platform technologies to other therapeutic areas such as selected eye diseases and have been exploring new applications of our technologies in other therapeutic areas."

For further information on the R&D briefing, taking place at 3pm today, please contact Mo Noonan at Financial Dynamics on 020 7831 3113.

Enquiries:

Contact details

Sinclair Pharma plc

Dr Michael Flynn, CEO

Jerry Randall ACA, CFO

John Barrington-Carver, Corp. PR

Tel: +44 (0) 1483 426 644

Tel: Mobile +44 (0) 7831 655 630

Financial Dynamics

Lucy Briggs

Tel +44 (0) 207 831 3113



Sinclair Pharma plc

Sinclair Pharma plc based in Godalming in the UK, is quoted on the Alternative Investment Market (AIM) on the London Stock Exchange and has focused on the acquisition and development of niche patented pharmaceutical products in the fields of oral health, oncology support and dermatology, and bringing them to the international market place via out-licensing partners. The Company combines product evaluation, product development, regulatory and business development expertise to add value to its acquired and in-house developed products. A key element of the Sinclair business model is to minimise risk and exposure by avoiding involvement in lengthy R&D programmes and rapidly achieving global distribution through a network of marketing partners. The Company has already licensed its products for distribution in over 40 countries around the world.

www.sinclairpharma.com

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward- looking statements due to a variety of factors.